

## Biotech company Biotts acquires PLN 7 m from investors

- The venture capital fund Montis Capital has invested over PLN 7 m in biotech company Biotts SA
- Biotts – a Wrocław-based start-up – develops innovative carriers of medical substances as well as drug compositions.  
Its flagship transdermal carrier can deliver particles deep into the skin.
- The biotech company has also recently signed a multi-million dollar agreement with Balanced Biotech. Working with this US company, Biotts will develop a drug to treat breast cancer.

*– Biotts has acquired a smart and experienced investor – one that will support our ambitious plans for development. We're getting ready to negotiate even more licencing agreements and believe that – by working with the Montis Capital team – not only will we be able to reach our business objectives faster, but our products will also become popular with clients worldwide – says Biotts VP Konrad Krajewski.*

*– I'm happy that we were able to conduct the second round of financing with Montis Capital efficiently. This capital will allow us to focus on our projects and on building the team – the company's CEO Dr. Paweł Biernat adds.*

The company will use the funding for example to continue current research on drugs, develop new products, and bring existing technologies to market. Nearly half of the invested funds will be used to develop new drugs, while PLN 1.5 m will go toward creating new, patented solutions and extending the protection provided by pending patents.

*– We discovered that the technologies developed by Biotts have a wide range of applications – the solutions developed by the company's team are a platform – this means that its patents can be utilized in many areas of medicine and the pharmaceutical industry. This translates into the ability to generate several streams of income from licencing agreements for a single patented technology – says Tomasz Poniński – Montis Capital Founder and Managing Partner. – We have a lot of faith in the projects the Biotts is carrying out. The company was created less than two years ago and it has already signed its first licencing agreement – with the American company Balanced Biotech – together the two entities are working on treatment for breast cancer – he adds.*

*– What would I compare our system to? Our carrier functions a lot like the “emergency corridors” on highways. An ambulance passes and traffic on the road returns to normal. Our system works the same way: it “softens” the cement between cells long enough for the active substance to reach the body painlessly – explains Paweł Biernat.*



The technology developed by Biotts can be used in the treatment of various diseases – not only as a delivery system for popular oncological drugs, but also frequently used anti-inflammatory, pain, and other medication. Using funding from the National Centre for Research and Development (NCBR), the company is developing a product that will make it possible to administer drugs externally: with an innovative carrier that can deliver substances for the treatment of diabetes and other diseases through the skin. Importantly, Biotts is currently conducting negotiations with another US company regarding a project that utilizes the transdermal system for the delivery of pain medication.

---

The biotechnological market, which is the market on which Biotts operates, has been growing for the past few years. This does not change the fact however that the best is yet to come, fuelled by innovative technologies and inquisitive researchers. According to an analysis by Global Market Insight, the biopharmaceutical market – alone will be worth USD 70 bn USD by the end of this year, and will exceed USD 110 bn by 2024. The market for transdermal systems is expected to be worth USD 7.1 bn by 2023. This growth is fuelled by an increase in the amount of cases of various chronic diseases and tech innovations in systems used to deliver drugs through the skin ([According to a Markets and Market report](#)).

**Biotts** – a Wrocław-based biotech company – develops its own drug compositions in the fields of oncology, dermatology and auto-immune diseases. The team of engineers at Biotts has developed the company’s proprietary technology for creating a universal system providing transdermal therapy. The system’s unique features increase the bioavailability of the active substances several times, which enables them to penetrate the skin at a depth of several centimetres, and allows them to reach the soft tissue as well as bones. The unique transdermal system developed by Biotts can deliver one or several active substances, enabling the design of drugs that are made up of several substances. The company also conducts research and development activities for international companies in the pharmaceutical, biotech, cosmetic and chemical industries.

More at [biotts.com](https://biotts.com)

---